LeiRui Medical Secures Over $40 Million in Series Angel and A Funding to Advance Neurovascular Intervention Innovations

VCBeatBe the first to know,SuZhou LavaMed Co.,Ltd.(abbreviated as“LavaMed) announced the consecutive completion of a cumulativeUltra 4000USD 10,000ofAngel Round andSeries A Financing。

The angel round of financing was invested by Lilly Asia Ventures; the Series A round was funded byZhejiang Minsheng Investment / Zhejiang Silk Road FundLead Investor, Junshang Capital、An Industrial Groupand existing shareholdersLilly Asia VenturesCo-investment. The financing proceeds will be used for the continuous R&D and production of the full portfolio of neurointerventional products.

LavaMed, established in August 2019, is a premium medical device manufacturer specializing in the field of neurointervention. The company is dedicated to the research, development, and manufacturing of high-quality, innovative neurointerventional medical devices, all of which possess independent intellectual property rights. Committed to excellence through innovation and meticulousness, LavaMed strives to create value for the advancement of global neurointerventional medicine, become the most trusted partner of neurosurgeons, and contribute to the treatment and rehabilitation of stroke patients. The company operates approximately 8,500 square meters of facilities, including office spaces, production plants, Class 10,000 cleanrooms, and world-leading production line equipment.

Actual Photos of LavaMed’s Corporate Environment

For this round of financing,LavaMed Founding Teamstated: "The Chinese neurointerventional medical device market is experiencing rapid growth, yet foreign brands still command over 90% of the market share. LavaMed is committed to comprehensively enhancing the manufacturing processes and quality standards for its neurointerventional products, while also exploring various applications of cutting-edge scientific technologies in the clinical treatment of brain disorders. LavaMed sincerely appreciates the support from all investors for the company's development and remains confident about its future prospects."”

Lilly Asia Ventures (LAV)stating, “The neurointerventional field is entering a period of rapid development and represents one of the most promising segments for innovative domestically produced medical devices. LavaMed benchmarks itself against world-class medical device companies, committing to the research, development, and manufacturing of best-in-class products. We believe that LavaMed will grow into an enterprise offering innovative therapeutic solutions with international competitiveness. It is our honor to grow alongside the company, and we will continue to firmly support SuZhou LavaMed Co., Ltd.”

Zhejiang United Investment Group / Zhejiang Silk Road Fund“The trend of domestic substitution in China’s neurointerventional device sector is gaining momentum, with broad prospects ahead. As a next-generation company in the neurointerventional field, LavaMed defines its products to meet international leading standards, and the design and features of several of its core products hold the potential to become best-in-class globally. We are honored to join the company’s shareholder base and look forward to providing long-term support for its development, aiming to accelerate the clinical application of its products to benefit patients.”